| Dermatitis, Atopic
Nemluvio vs Vtama
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Nemluvio vs Vtama with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVtama has a higher rate of injection site reactions vs Nemluvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vtama but not Nemluvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nemluvio
Vtama
At A Glance
SC injection
Every 4 weeks
IL-31 receptor antagonist
Topical
Daily
AhR agonist
Indications
- Prurigo nodularis
- Dermatitis, Atopic
- Psoriasis vulgaris
- Dermatitis, Atopic
Dosing
Prurigo nodularis (<90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks.
Prurigo nodularis (>=90 kg) Initial dose of 60 mg (two 30 mg injections) SC, followed by 60 mg SC every 4 weeks.
Dermatitis, Atopic Initial dose of 60 mg (two 30 mg injections) SC, followed by 30 mg SC every 4 weeks; after 16 weeks, patients who achieve clear or almost clear skin may receive 30 mg every 8 weeks.
Psoriasis vulgaris, Dermatitis, Atopic Apply a thin layer to affected areas once daily; wash hands after application unless VTAMA cream is for treatment of the hands; not for oral, ophthalmic, or intravaginal use.
Contraindications
- Known hypersensitivity to nemolizumab-ilto or any excipient in NEMLUVIO
—
Adverse Reactions
Most common (>=1%) Headache, dermatitis atopic, eczema, eczema nummular (prurigo nodularis trials); headache, arthralgia, urticaria, myalgia (atopic dermatitis trials).
Serious Type 1 hypersensitivity reactions (IgE-mediated), including facial angioedema.
Most common (>=1%) - Plaque Psoriasis Folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, influenza
Most common (>=1%) - Atopic Dermatitis Upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, abdominal pain
Pharmacology
Nemolizumab-ilto is a humanized IgG2 monoclonal antibody that inhibits IL-31 signaling by binding selectively to IL-31 receptor alpha (IL-31 RA); IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation, and fibrosis.
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist; the specific mechanisms by which VTAMA cream exerts its therapeutic actions in plaque psoriasis and atopic dermatitis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nemluvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Vtama
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Nemluvio
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (4/8)
Vtama
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Nemluvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Vtama
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NemluvioView full Nemluvio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.